Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy

• Published in: Seminars in cancer biology 2022-11, Vol.86 (Pt 3), p.69-83
• Main Authors: Mir, C., Garcia-Mayea, Y., LLeonart, M.E.
• Format: Article
• Language: English
• Subjects: Cancer; Chemoresistance; Humans; Neoplasms - drug therapy; Neoplasms - genetics; Protein Biosynthesis; RNA, Messenger - genetics; RNA, Messenger - metabolism; RNA-binding proteins (RBPs); RNA-Binding Proteins - chemistry; RNA-Binding Proteins - genetics; RNA-Binding Proteins - metabolism; Therapy
• ISSN: 1044-579X; 1096-3650
• DOI: 10.1016/j.semcancer.2022.06.008

Tumors refractory to conventional therapy belong to specific subpopulations of cancer cells, which have acquired a higher number of mutations/epigenetic changes than the majority of cancer cells. This property provides them the ability to become resistant to therapy. Aberrant expression of certain RNA-binding proteins (RBPs) can regulate the sensitivity of tumor cells to chemotherapeutic drugs by binding to specific regions present in the 3´-UTR of certain mRNAs to promote or repress mRNA translation or by interacting with other proteins (including RBPs) and non-coding RNAs that are part of ribonucleoprotein complexes. In particular, an increasing interest in the RBPs involved in chemoresistance has recently emerged. In this review, we discuss how RBPs are not only affected by chemotherapeutic treatments, but also play an active role in therapeutic responses via the direct modulation of crucial cancer-related proteins. A special focus is being placed on the development of therapeutic strategies targeting these RBPs.